Implantica AG (8IM1.F)

2.3250 -0.0250 (-1.06%) As of 04:15PM CEST. Market open.

Implantica AG

Aeulestrasse 45
Vaduz 9490
Liechtenstein

https://www.implantica.com

Sector(s): Healthcare
Industry: Medical Devices
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Peter Forsell	Founder & CEO	202.35k	N/A	1954
Mr. Andreas Öhrnberg	Chief Financial Officer	N/A	N/A	1978
Mr. Stephan Siegenthaler	Chief Strategy Officer & Board Member	N/A	N/A	1957
Ms. Nicole Pehrsson	Chief Corporate Affairs Officer	N/A	N/A	1966
Mr. Stefan Vogt	Chief Commercial Officer	N/A	N/A	1965
Mr. Amit Kukreja	Chief Market Access & Strategy Officer	N/A	N/A	1983
Mr. Jörg von Manger-Koenig	Company Secretary & Member of Advisory Board	N/A	N/A	1960

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Implantica AG engages in the research and distribution of medical implants in Switzerland. The company's lead product candidate is RefluxStop, a passive CE-marked implant for prevention of gastroesophageal reflux disease. It is also involved in the development of eHealth platform, a digital health system to support its pipeline of smart medical implants designed for a safe and secure control and monitoring over the internet; e-InVivo, a sensor implants to monitor a multitude of health parameters and provide diagnostic information, as well as control treatment from inside the body; wireless energizing platform; and AppetiteControl, an implant to treat obesity by controlling appetite. In addition, the company develops UriControl, a remote controlled artificial urinary sphincter to treat urinary incontinence for men and women; and UriRestor, a remote-controlled device that enables spinal cord injury and multiple sclerosis patients to urinate on demand using the wireless platform. Further, it provides PotencyFlow for treatment of erectile dysfunction; StomaRestore for eliminating stoma bags; RectalRestore for treatment of fecal incontinence; and AneurysmControl for the treatment of aneurysms. The company was founded in 2015 and is based in Vaduz, Liechtenstein.

Corporate governance

Implantica AG’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.